Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer

Sorbe, Bengt; Graflund, Marianne; Horváth, György; Swahn, Marie; Boman, Kurt; Bangshöj, René; Lood, Margareta; Malmström, Henric

doi:10.1097/igc.0b013e318234fa3a

Cited by 11 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical and biochemical response rates were based on patients with measurable disease and/or elevated CA-125 levels at the start of chemotherapy. The results from a phase II study of weekly treatment have been published previously (17). Toxicity, which is the main topic of this study, was recorded in all 167 patients (≥1 course of chemotherapy).…”

Section: Methodsmentioning

confidence: 99%

“…A chemotherapy regimen of weekly docetaxel 30 mg/m 2 and carboplatin [area under the curve (AUC) 5] was given every 3 weeks to 108 patients (17). Six cycles were administered during 18 weeks.…”

Section: Methodsmentioning

confidence: 99%

“…More dose-dense weekly schedules have also been studied in small patient series of recurrent ovarian cancer (10–16). New data on up-front weekly docetaxel with regard to efficacy, toxicity and quality of life have recently been presented (17,18). …”

Section: Introductionmentioning

confidence: 99%

“…In both schedules carboplatin was administered every three weeks. Efficacy and quality-of-life data have been presented previously and are not analyzed in this study (17,18). …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles

et al. 2013

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to compare the toxicity profiles of docetaxel administered on a weekly schedule and the standard three-week schedule in the treatment of advanced primary ovarian carcinoma. Eligible patients were treated with intravenous docetaxel (30 mg/m2) on days 1, 8 and 15, and carboplatin (AUC 5) on day 1 or with docetaxel (75 mg/m2) and carboplatin (AUC 5) on day 1; Q21 days for 6 cycles. This study was a pooled study of two primary phase II studies. A total of 108 patients received the weekly schedule and 59 patients received the three-week schedule. All patients were evaluated for toxicity. The overall response rate was 79% and the biochemical response 93% for the weekly schedule. The median overall survival rate was 35.3 months. Neutropenia was significantly more common (ANOVA; p<0.0001) in the three-week group than in the weekly group during all six courses of chemotherapy. Fever and infections were also more common in this group. Thrombocytopenia and anemia were slightly more common in the weekly group. Fatigue, epiphora, nail changes and taste disturbances were specific side-effects following weekly docetaxel. Peripheral sensory neuropathy (grade 1–2) increased with every cycle of treatment, but in a similar manner in the two groups. Grade 3–4 neuropathy was not recorded. Oral mucositis and myalgia were two side-effects associated with the three-week schedule. Nausea and vomiting, diarrhea and dyspnea were a limited problem in both groups. Cardiac toxicity was rare and did not differ between the two docetaxel schedules. The weekly administration was favored due to the lower rates of neutropenia, fever, infections, oral mucositis and myalgia. However, epiphora and nail changes were specific side-effects of the weekly treatment. Both regimens appeared to be rather well tolerated with similar compliance (66 and 70%) with regard to completion of the planned six courses of chemotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…In both schedules carboplatin was administered every three weeks. Efficacy and quality-of-life data have been presented previously and are not analyzed in this study (17,18). …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…The latter includes young patients, patients with hormone receptornegative breast cancer, patients with nodal involvement, or patients with poorly differentiated tumor cells (Green and Hortobagye, 2007;Kobayashi et al, 2012). Docetaxel is also approved for treatment of other solid tumors, including nonsmall cell lung cancer, ovarian cancer, gastric cancer, and prostate cancer (Cui et al, 2012;Petrani et al, 2012;Sorbe et al, 2012;Milanowski et al, 2013). In patients with locally advanced or metastatic breast cancer, the recommended dosage is 60 mg/m 2 to 100 mg/m 2 given intravenously over 1 hour every 3 weeks.…”

Section: Introductionmentioning

confidence: 97%

Pharmacogenomics Variation in Drug Metabolizing Enzymes and Transporters in Relation to Docetaxel Toxicity in Lebanese Breast Cancer Patients: Paving the Way for OMICs in Low and Middle Income Countries

Awada

Haider

Tfayli

et al. 2013

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

We investigated the association of genetic polymorphisms in drug metabolizing enzymes (DMEs) and transporters in patients with docetaxel-induced febrile neutropenia, by a new high-throughput DMEs and transporters (DMETPlus) microarray platform, characterizing 1936 single nucleotide polymorphisms (SNPs) in 225 genes. We recruited 100 Lebanese breast cancer patients from a consecutive cohort of 277 patients who received docetaxel either alone, or in combination with trastuzumab. Out of 100 patients, 18 had developed febrile neutropenia (cases). They were age- and treatment- matched with 18 patients who did not develop febrile neutropenia on docetaxel (controls). We found that 12 SNPs in seven genes (ABCC6, ABCG1, ABCG2, CYP1A2, CYP2D6, FMO2, and FMO3) were significantly associated with febrile neutropenia after docetaxel treatment. Many of these SNPs have not been previously reported to be associated with toxicity due to docetaxel treatment. Interestingly, one SNP in the FMO3 gene (rs909530) was significantly associated with three clinical endpoints: febrile neutropenia, reduced absolute neutrophil count, and hemoglobin reduction. To the best of our knowledge, this is the first study that evaluated the effect of a large array of nearly 2000 polymorphisms in DMEs and transporters on docetaxel toxicity in breast cancer patients, and in a previously understudied population. Additionally, it attests to the feasibility of genomics research in low- and middle-income countries (LMICs). In light of the current global epidemic of noncommunicable diseases (NCDs) such as breast cancer impacting LMICs, we suggest pharmacogenomics is considered as an integral part of the global health research agenda for NCDs and personalized therapeutics.

show abstract

Docetaxel Nanotechnology in Anticancer Therapy

2012

View full text Add to dashboard Cite

Taxanes have been recognized as a family of very efficient anticancer drugs, but the formulation in use for the two main taxanes-Taxol for paclitaxel and Taxotere for docetaxel-have shown dramatic side effects. Whereas several new formulations for paclitaxel have recently appeared, such as Abraxane and others currently in various phases of clinical trials, there is no new formulation in clinical trials for the other main taxane, docetaxel, except BIND-014, a polymeric nanoparticle, which recently entered phase I clinical testing. Therefore, we review herein the state of the art and recent abundance in published results of academic approaches toward nanotechnology-based drug-delivery systems containing nanocarriers and targeting agents for docetaxel formulations. These efforts will certainly enrich the spectrum of docetaxel treatments in the near future. Taxotere's systemic toxicity, low water solubility, and other side effects are significant problems that must be overcome. To avoid the limitations of docetaxel in clinical use, researchers have developed efficient drug-delivery assemblies that consist of a nanocarrier, a targeting agent, and the drug. A wide variety of such engineered nanosystems have been shown to transport and eventually vectorize docetaxel more efficiently than Taxotere in vitro, in vivo, and in pre-clinical administration. Recent progress in drug vectorization has involved a combined therapy and diagnostic ("theranostic") approach in a single drug-delivery vector and could significantly improve the efficiency of such an anticancer drug as well as other drug types.

show abstract

Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer

Cited by 11 publications

References 24 publications

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles

Pharmacogenomics Variation in Drug Metabolizing Enzymes and Transporters in Relation to Docetaxel Toxicity in Lebanese Breast Cancer Patients: Paving the Way for OMICs in Low and Middle Income Countries

Docetaxel Nanotechnology in Anticancer Therapy

Contact Info

Product

Resources

About